Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel

Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Yuki, Ando, Takayuki, Hosokawa, Ayumu, Mihara, Hiroshi, Takagi, Hiroaki, Nakata, Naokatsu, Yoshita, Hiroki, Nanjo, Sohachi, Kajiura, Shinya, Fujinami, Haruka, Sugiyama, Toshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874337/
https://www.ncbi.nlm.nih.gov/pubmed/29151523
http://dx.doi.org/10.2169/internalmedicine.9369-17
Descripción
Sumario:Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received ramucirumab plus paclitaxel; this treatment was chosen because vascular endothelial growth factor 2 was strongly expressed in the tumor endothelial cells. After two cycles, his NEC had markedly reduced in size, and he continued with this treatment for over eight months. In this case, the combination of an anti-angiogenic inhibitor and a cytotoxic agent was highly effective for gastric NEC.

Ejemplares similares